Covered recipient · General Payments record
AWAWU E IGBINADOLOR
Allopathic & Osteopathic Physicians Internal Medicine Adolescent Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$15.40
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $15.40 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Exact Sciences Corporation | $15.40 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AWAWU E IGBINADOLOR
NPI 1386658128 · CMS profile ID 334690
Allopathic & Osteopathic Physicians / Internal Medicine / Adolescent Medicine
MONROE, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1386658128?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386658128?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386658128?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1386658128?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $15.40 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | $15.40 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235621385 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $5,807,545.77 | 332 |
| PY2024 | Recipient | $24,803.18 | 2 |
| PY2024 | Principal investigator | $5,575,092.65 | 467 |
| PY2023 | Recipient | $5,441.70 | 12 |
| PY2023 | Principal investigator | $4,002,304.15 | 759 |
| PY2022 | Recipient | $99,385.00 | 2 |
| PY2022 | Principal investigator | $3,185,482.26 | 500 |
| PY2021 | Recipient | $421,014.16 | 3 |
| PY2021 | Principal investigator | $3,556,229.85 | 34 |
| PY2020 | Recipient | $145,488.66 | 2 |
| PY2019 | Principal investigator | $9,471.00 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
332 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $19,416.63 | 12/31/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression | No dispute reported | 06/30/2026 | 1232929099 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $274.40 | 12/31/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression | No dispute reported | 06/30/2026 | 1232929101 |
| Principal investigator 1 | Amgen Inc. | $19,300.00 | 12/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure Therapy and Living With Overweight or Obesity (MARITIME-OSA-2) | No dispute reported | 06/30/2026 | 1246644803 |
| Principal investigator 1 | Amgen Inc. | $20,348.00 | 12/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity | No dispute reported | 06/30/2026 | 1246644807 |
| Principal investigator 1 | Genentech, Inc. | $2,838.00 | 12/23/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC | No dispute reported | 06/30/2026 | 1211626327 |
| Principal investigator 1 | Eli Lilly and Company | $10,000.00 | 12/22/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES (SYNERGY-OUTCOMES); N1T-MC-TZ01; N1T-MC-RT01 | No dispute reported | 06/30/2026 | 1187887774 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 12/22/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC | No dispute reported | 06/30/2026 | 1211626315 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 12/22/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC | No dispute reported | 06/30/2026 | 1211626318 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 12/22/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A PHASE IIb TO ASSESS THE EFFICACY, SAFETY, AND PHARMAKOKINETICS OF RO7837195 in Patients with UC | No dispute reported | 06/30/2026 | 1211626321 |
| Principal investigator 1 | PFIZER INC. | $432.00 | 12/20/2025 | Non-covered Recipient Entity Monroe Biomedical Research | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228746312 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $4,643.57 | 12/19/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514720 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $503.86 | 12/19/2025 | Non-covered Recipient Entity Monroe Biomedical Research Monroe | A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers | No dispute reported | 06/30/2026 | 1226102394 |
| Principal investigator 1 | Verona Pharma, Inc. | $850.00 | 12/19/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891527 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,000.00 | 12/19/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891529 |
| Principal investigator 1 | Seqirus USA Inc | $472.50 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288080 |
| Principal investigator 1 | Seqirus USA Inc | $472.50 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288082 |
| Principal investigator 1 | Seqirus USA Inc | $472.50 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288084 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288212 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288214 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288216 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288270 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288272 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288274 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288276 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288278 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288280 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288282 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288284 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288286 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288288 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288290 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288302 |
| Principal investigator 1 | Seqirus USA Inc | $1,352.40 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288304 |
| Principal investigator 1 | Seqirus USA Inc | $1,352.40 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288306 |
| Principal investigator 1 | Seqirus USA Inc | $1,352.40 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288308 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288448 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288450 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288452 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288454 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288456 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288461 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288464 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288466 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288468 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288470 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288472 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288474 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288476 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288478 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288480 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288482 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288484 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288486 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288488 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288490 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288492 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288494 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288496 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288498 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288500 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288502 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288504 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288506 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288508 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288510 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288512 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288514 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288516 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288518 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288520 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288522 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288524 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288526 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288528 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288530 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288532 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288562 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288564 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288566 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288568 |
| Principal investigator 1 | Seqirus USA Inc | $4,062.10 | 12/18/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185288570 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 12/17/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514707 |
| Principal investigator 1 | Eli Lilly and Company | $915.38 | 12/17/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187885520 |
| Principal investigator 1 | Eli Lilly and Company | $934.02 | 12/17/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187886584 |
| Principal investigator 1 | Verona Pharma, Inc. | $328.44 | 12/12/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891599 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 12/10/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514672 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 12/10/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514681 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6,729.80 | 12/10/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514689 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 12/10/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514692 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 12/10/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514716 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $100.00 | 12/10/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514732 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $800.00 | 12/10/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514742 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 12/05/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514700 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 12/01/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514696 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,417.60 | 12/01/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514747 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 11/29/2025 | Non-covered Recipient Entity Monroe Biomedical Research | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228737506 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,573.10 | 11/25/2025 | Non-covered Recipient Entity Monroe Biomedical Research Monroe | A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers | No dispute reported | 06/30/2026 | 1226102354 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $80,150.43 | 11/24/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression | No dispute reported | 06/30/2026 | 1232929097 |
| Principal investigator 1 | ModernaTX, Inc. | $5,882.16 | 11/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966005 |
| Principal investigator 1 | ModernaTX, Inc. | $6,021.04 | 11/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966009 |
| Principal investigator 1 | ModernaTX, Inc. | $5,065.20 | 11/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966011 |
| Principal investigator 1 | ModernaTX, Inc. | $3,446.52 | 11/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966013 |
| Principal investigator 1 | ModernaTX, Inc. | $17,451.84 | 11/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966021 |
| Principal investigator 1 | ModernaTX, Inc. | $1,067.58 | 11/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966043 |
| Principal investigator 1 | ModernaTX, Inc. | $17,532.45 | 11/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966063 |
| Principal investigator 1 | ModernaTX, Inc. | $3,642.60 | 11/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966067 |
| Principal investigator 1 | ModernaTX, Inc. | $20,710.08 | 11/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966069 |
| Principal investigator 1 | ModernaTX, Inc. | $862.54 | 11/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966071 |
| Principal investigator 1 | ModernaTX, Inc. | $8,524.10 | 11/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966081 |
| Principal investigator 1 | ModernaTX, Inc. | $1,774.71 | 11/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966083 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $400.00 | 11/21/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514663 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $200.00 | 11/21/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514668 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $574.56 | 11/21/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514685 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $400.00 | 11/21/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514728 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,600.00 | 11/21/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514739 |
| Principal investigator 1 | ModernaTX, Inc. | $58.59 | 11/21/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966077 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 11/19/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514704 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $800.00 | 11/19/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514736 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 11/19/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966045 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,356.43 | 11/14/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514676 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $750.00 | 11/14/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514712 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $250.00 | 11/14/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514724 |
| Principal investigator 1 | ModernaTX, Inc. | $30.00 | 11/07/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966041 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $850.00 | 11/05/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DEMONSTRAT | No dispute reported | 06/30/2026 | 1192098254 |
| Principal investigator 1 | PFIZER INC. | $598.00 | 11/04/2025 | Non-covered Recipient Entity Monroe Biomedical Research | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228739272 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $341.00 | 11/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514658 |
| Principal investigator 1 | Verona Pharma, Inc. | $37,192.20 | 11/03/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891535 |
| Principal investigator 1 | Verona Pharma, Inc. | $2,000.00 | 11/03/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891619 |
| Principal investigator 1 | Seqirus USA Inc | $4,103.04 | 10/31/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250810104 |
| Principal investigator 1 | Seqirus USA Inc | $1,127.52 | 10/31/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250810108 |
| Principal investigator 1 | ModernaTX, Inc. | $208.07 | 10/29/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966037 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $16,652.30 | 10/28/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH, LLC | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185545279 |
| Principal investigator 1 | ModernaTX, Inc. | $2,177.28 | 10/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966089 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,199.39 | 10/22/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514750 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 10/22/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966035 |
| Principal investigator 1 | ModernaTX, Inc. | $30.00 | 10/22/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966055 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 10/16/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966019 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 10/16/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966065 |
| Principal investigator 1 | Seqirus USA Inc | $13,500.00 | 10/16/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185290338 |
| Principal investigator 1 | Seqirus USA Inc | $3,000.00 | 10/16/2025 | Non-covered Recipient Entity Pharmaseek LLC | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185290344 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 10/08/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966023 |
| Principal investigator 1 | ModernaTX, Inc. | $30.00 | 10/08/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966087 |
| Principal investigator 1 | Genentech, Inc. | $284.98 | 10/03/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626307 |
| Principal investigator 1 | Genentech, Inc. | $850.00 | 10/03/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626311 |
| Principal investigator 1 | Verona Pharma, Inc. | $328.44 | 10/03/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891585 |
| Principal investigator 1 | ModernaTX, Inc. | $1,250.00 | 10/01/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966059 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,500.00 | 09/25/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH, LLC | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190305229 |
| Principal investigator 1 | PFIZER INC. | $1,794.00 | 09/24/2025 | Non-covered Recipient Entity Monroe Biomedical Research | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228750625 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 09/19/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514627 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $37,900.86 | 09/19/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH, LLC | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185545273 |
| Principal investigator 1 | ModernaTX, Inc. | $4,627.53 | 09/19/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966101 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,500.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514645 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $326.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514649 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $48.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514653 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $326.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514847 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $48.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514852 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $101.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514856 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $384.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514859 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $110.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514863 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $273.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514868 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514871 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $280.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514875 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $546.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514878 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $341.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514883 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $978.00 | 09/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514888 |
| Principal investigator 1 | Verona Pharma, Inc. | $850.00 | 09/12/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891451 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $50.00 | 09/10/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514798 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,157.00 | 09/10/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH, LLC | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185545277 |
| Principal investigator 1 | PFIZER INC. | $2,160.00 | 09/09/2025 | Non-covered Recipient Entity Monroe Biomedical Research | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228750749 |
| Principal investigator 1 | Seqirus USA Inc | $111.30 | 09/09/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283601 |
| Principal investigator 1 | Seqirus USA Inc | $177.19 | 09/09/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283605 |
| Principal investigator 1 | Seqirus USA Inc | $789.00 | 09/09/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283609 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,771.93 | 09/08/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH, LLC | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190309762 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $3,000.00 | 09/05/2025 | Non-covered Recipient Entity DRUG STUDIES AMERICA | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067729 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514803 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,406.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514808 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,057.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514812 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,331.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514816 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,050.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514820 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $520.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514823 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,668.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514827 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,350.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514831 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,895.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514836 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $846.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514840 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $50,425.50 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514844 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514891 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514894 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514898 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514902 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514906 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514910 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514913 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514918 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514922 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514925 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514928 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514931 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514936 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,057.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514940 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514943 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514947 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514951 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514955 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514959 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514964 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514968 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,057.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514971 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,057.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514975 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,057.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514979 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514985 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,057.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514989 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,057.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514992 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,845.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215514997 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,406.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215515001 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,057.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215515005 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,057.00 | 09/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215515011 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,499.00 | 09/03/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DEMONSTRAT | No dispute reported | 06/30/2026 | 1192098239 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,500.00 | 09/03/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DEMONSTRAT | No dispute reported | 06/30/2026 | 1192098247 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 09/02/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966073 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $850.00 | 08/26/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626223 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $73,396.54 | 08/22/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH, LLC | a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure | No dispute reported | 06/30/2026 | 1185545275 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,034.60 | 08/20/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH, LLC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185545271 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,000.00 | 08/20/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891517 |
| Principal investigator 1 | ModernaTX, Inc. | $180.00 | 08/08/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966027 |
| Principal investigator 1 | ModernaTX, Inc. | $60.00 | 08/08/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966049 |
| Principal investigator 1 | ModernaTX, Inc. | $60.00 | 08/08/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966057 |
| Principal investigator 1 | ModernaTX, Inc. | $472.80 | 08/08/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966095 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $50.00 | 08/06/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514779 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 08/05/2025 | Non-covered Recipient Entity Monroe Biomedical Research | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228766907 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 08/01/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514794 |
| Principal investigator 1 | Amgen Inc. | $107,384.73 | 08/01/2025 | Non-covered Recipient Entity CLINITIATIVE LLC CLINITIATIVE HEALTH RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246640407 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 08/01/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966031 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $243.00 | 07/31/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626232 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,229.00 | 07/31/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626239 |
| Principal investigator 1 | Amgen Inc. | $247,453.03 | 07/28/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246644799 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 07/28/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966007 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 07/25/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514782 |
| Principal investigator 1 | Verona Pharma, Inc. | $10,000.00 | 07/25/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891473 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,852.00 | 07/25/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891475 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,000.00 | 07/25/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891511 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $463.07 | 07/22/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626226 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,229.00 | 07/22/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626236 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,229.00 | 07/22/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626242 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $50.00 | 07/18/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514775 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $50.00 | 07/18/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514786 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $150.00 | 07/18/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514791 |
| Principal investigator 1 | ModernaTX, Inc. | $6,191.64 | 07/18/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966051 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $29,869.47 | 07/16/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514772 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $500.00 | 07/11/2025 | Non-covered Recipient Entity Research Mate Inc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067019 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 07/11/2025 | Non-covered Recipient Entity Monroe Biomedical Research | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228782280 |
| Principal investigator 1 | Amgen Inc. | $25,433.65 | 06/26/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246644811 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $22,215.23 | 06/24/2025 | Non-covered Recipient Entity Monroe Biomedical Research, Llc | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease | No dispute reported | 06/30/2026 | 1235995633 |
| Principal investigator 1 | ModernaTX, Inc. | $30.00 | 06/20/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966033 |
| Principal investigator 1 | ModernaTX, Inc. | $2,347.38 | 06/20/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966053 |
| Principal investigator 1 | Genentech, Inc. | $66.00 | 06/19/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211626245 |
| Principal investigator 1 | Genentech, Inc. | $243.00 | 06/19/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211626273 |
| Principal investigator 1 | Genentech, Inc. | $5,649.00 | 06/19/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211626280 |
| Principal investigator 1 | ModernaTX, Inc. | $32,784.80 | 06/18/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966079 |
| Principal investigator 1 | Genentech, Inc. | $2,440.11 | 06/12/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211626256 |
| Principal investigator 1 | Genentech, Inc. | $243.00 | 06/05/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211626252 |
| Principal investigator 1 | Genentech, Inc. | $1,515.97 | 06/05/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211626268 |
| Principal investigator 1 | Genentech, Inc. | $3,058.00 | 06/05/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211626285 |
| Principal investigator 1 | Genentech, Inc. | $81.00 | 06/05/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626293 |
| Principal investigator 1 | Genentech, Inc. | $243.00 | 06/05/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626298 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 06/04/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966017 |
| Principal investigator 1 | ModernaTX, Inc. | $60.00 | 06/04/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966025 |
| Principal investigator 1 | Eli Lilly and Company | $6,730.63 | 06/02/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187887428 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 05/28/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966085 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 05/28/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966091 |
| Principal investigator 1 | ModernaTX, Inc. | $2,100.13 | 05/23/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966039 |
| Principal investigator 1 | Bausch Health US, LLC | $131.00 | 05/14/2025 | Non-covered Recipient Entity Research Mate Inc | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224845027 |
| Principal investigator 1 | ModernaTX, Inc. | $30.00 | 05/14/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966047 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $150.00 | 05/07/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514754 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,100.00 | 05/07/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514758 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $100.00 | 05/07/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514763 |
| Principal investigator 1 | PFIZER INC. | $552.00 | 05/06/2025 | Non-covered Recipient Entity Monroe Biomedical Research | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228722872 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,600.00 | 04/28/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation | No dispute reported | 06/30/2026 | 1226128731 |
| Principal investigator 1 | ModernaTX, Inc. | $1,343.79 | 04/23/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966093 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $107,168.80 | 04/16/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215514768 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 04/11/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215515042 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 04/03/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211626265 |
| Principal investigator 1 | Genentech, Inc. | $10,000.00 | 04/03/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211626276 |
| Principal investigator 1 | Bausch Health US, LLC | $2,250.00 | 04/02/2025 | Non-covered Recipient Entity Research Mate Inc | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224845042 |
| Principal investigator 1 | Bausch Health US, LLC | $1,900.00 | 04/02/2025 | Non-covered Recipient Entity Research Mate Inc | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224845045 |
| Principal investigator 1 | Bausch Health US, LLC | $1,300.00 | 04/02/2025 | Non-covered Recipient Entity Research Mate Inc | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) | No dispute reported | 06/30/2026 | 1224845063 |
| Principal investigator 1 | Eli Lilly and Company | $23,838.00 | 04/01/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187884282 |
| Principal investigator 1 | ModernaTX, Inc. | $60.00 | 04/01/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966029 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 04/01/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966097 |
| Principal investigator 1 | ModernaTX, Inc. | $1,370.52 | 03/24/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966061 |
| Principal investigator 1 | ModernaTX, Inc. | $260.50 | 03/21/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966075 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $23,596.67 | 03/18/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH, LLC | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients | No dispute reported | 06/30/2026 | 1190309758 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $20,023.10 | 03/12/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215515030 |
| Principal investigator 1 | Genentech, Inc. | $344.69 | 03/11/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626248 |
| Principal investigator 1 | Genentech, Inc. | $1,098.70 | 03/11/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626261 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $143.96 | 03/07/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM | No dispute reported | 06/30/2026 | 1215515027 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $18,450.00 | 03/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM | No dispute reported | 06/30/2026 | 1215515015 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $77,736.79 | 03/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM | No dispute reported | 06/30/2026 | 1215515019 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 03/03/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM | No dispute reported | 06/30/2026 | 1215515024 |
| Principal investigator 1 | PFIZER INC. | $15,014.40 | 02/22/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228759293 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 02/20/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626289 |
| Principal investigator 1 | Genentech, Inc. | $10,000.00 | 02/20/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH LLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211626303 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $66,141.95 | 02/19/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215515034 |
| Principal investigator 1 | Eli Lilly and Company | $34,448.73 | 02/14/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | No dispute reported | 06/30/2026 | 1187884280 |
| Principal investigator 1 | Eli Lilly and Company | $91,324.28 | 02/14/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187884284 |
| Principal investigator 1 | Eli Lilly and Company | $692,607.18 | 02/14/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187886580 |
| Principal investigator 1 | Eli Lilly and Company | $2,200.00 | 02/14/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187886582 |
| Principal investigator 1 | Eli Lilly and Company | $3,561.88 | 02/14/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | No dispute reported | 06/30/2026 | 1187886586 |
| Principal investigator 1 | PFIZER INC. | $14,750.00 | 02/06/2025 | Non-covered Recipient Entity Monroe Biomedical Research | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228723468 |
| Principal investigator 1 | PFIZER INC. | $3,750.00 | 02/04/2025 | Non-covered Recipient Entity Monroe Biomedical Research | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228753528 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $30.00 | 01/31/2025 | Non-covered Recipient Entity Monroe Biomedical Research | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215520480 |
| Principal investigator 1 | Eli Lilly and Company | $360.00 | 01/31/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1187887130 |
| Principal investigator 1 | Eli Lilly and Company | $19,455.25 | 01/31/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187887422 |
| Principal investigator 1 | ModernaTX, Inc. | $71,267.04 | 01/29/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252966015 |
| Principal investigator 1 | ModernaTX, Inc. | $680.40 | 01/29/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252966099 |
| Principal investigator 1 | Eli Lilly and Company | $506.75 | 01/27/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | No dispute reported | 06/30/2026 | 1187884870 |
| Principal investigator 1 | Eli Lilly and Company | $9,926.99 | 01/27/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | No dispute reported | 06/30/2026 | 1187885518 |
| Principal investigator 1 | Eli Lilly and Company | $858.02 | 01/27/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | No dispute reported | 06/30/2026 | 1187887776 |
| Principal investigator 1 | Eli Lilly and Company | $3,370.36 | 01/22/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187885042 |
| Principal investigator 1 | Eli Lilly and Company | $465,199.24 | 01/21/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187886578 |
| Principal investigator 1 | Eli Lilly and Company | $11,540.93 | 01/09/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187885024 |
| Principal investigator 1 | Eli Lilly and Company | $6,070.00 | 01/09/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187887424 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $34,239.89 | 01/09/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH, LLC | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190309760 |
| Principal investigator 1 | Eli Lilly and Company | $971,483.57 | 01/07/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187884286 |
| Principal investigator 1 | Eli Lilly and Company | $205,542.11 | 01/07/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187887128 |
| Principal investigator 1 | Eli Lilly and Company | $502,754.65 | 01/07/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | No dispute reported | 06/30/2026 | 1187887420 |
| Principal investigator 1 | Eli Lilly and Company | $704,881.98 | 01/07/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187887426 |
| Principal investigator 1 | Eli Lilly and Company | $719.58 | 01/06/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | No dispute reported | 06/30/2026 | 1187885022 |
| Principal investigator 1 | AstraZeneca UK Limited | $41,711.85 | 01/03/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH, LLC | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185545269 |
| Principal investigator 1 | Eli Lilly and Company | $9,889.67 | 01/02/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187885044 |
| Principal investigator 1 | Eli Lilly and Company | $8,185.92 | 01/02/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187885046 |
| Principal investigator 1 | Eli Lilly and Company | $27,938.63 | 01/02/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE | No dispute reported | 06/30/2026 | 1187885884 |
| Principal investigator 1 | Eli Lilly and Company | $857.26 | 01/02/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | No dispute reported | 06/30/2026 | 1187887132 |